Qualigen Therapeutics News

Express News | Marizyme Inc - Qualigen Purchased Exclusive Negotiation Period Ending May 31 for Proposing Broader Strategic Relationship Between Two Companies

Moomoo 24/7Apr 16 07:02 ET

Express News | Marizyme Inc - Qualigen Will Help Support Commercial Launch in United States of Duragraft

Moomoo 24/7Apr 16 07:00 ET

Express News | Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared Duragraft™

Moomoo 24/7Apr 16 07:00 ET

Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting

Qualigen Therapeutics, Inc. （Nasdaq: QLGN) today announces a poster presentation on its preclinical Novel Direct Pan-RAS Inhibitors was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 held April 5 – 10 in San Diego, California.

GlobeNewswireApr 10 08:00 ET

Express News | Qualigen Therapeutics Highlights Poster Featuring Early Clinical Experience With QN-302 At American Association Of Cancer Research 2024 Annual Meeting

Moomoo 24/7Apr 9 09:34 ET

Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience With QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting

CARLSBAD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. ("Qualigen" or the "Company," Nasdaq: QLGN) today announces that a poster featuring its early clinical experience wit

GlobeNewswireApr 9 08:00 ET

Qualigen Therapeutics Ends Deal With Pan-RAS Holdings

TipRanksMar 28 16:25 ET

12 Health Care Stocks Moving In Tuesday's Intraday Session

GainersJanux Therapeutics (NASDAQ:JANX) stock increased by 189.9% to $43.78 during Tuesday's regular session. The company's market cap stands at $2.0 billion. Viking Therapeutics (NASDAQ:VKTX) shares

BenzingaFeb 27 12:31 ET

Qualigen Therapeutics Secures Investment and Expands Financing Options

TipRanksFeb 27 07:12 ET

Qualigen Therapeutics Inks Exclusive RAS Program Deal

TipRanksFeb 22 16:25 ET

Express News | Qualigen Therapeutics New Publication Released In The Nature Scientific Reports Journal Titled "Structure–Activity Relationships For The G-Quadruplex-Targeting Experimental Drug QN-302 And Two Analogues Probed With Comparative Transcriptome Profiling And

Moomoo 24/7Feb 12 11:51 ET

Qualigen Therapeutics Provides Corporate Update For Q3 And To Date 2023

Initiated dosing of three patients in first cohort of Phase 1 clinical trial of QN-302 for treatment of advanced or metastatic solid tumorsPhase 1a patient recruitment ongoing; company anticipates sha

BenzingaNov 14, 2023 17:41 ET

Qualigen Therapeutics Announces First Patient Dosed In The Phase 1a Clinical Trial Of QN-302 For Treatment Of Advanced Or Metastatic Solid Tumors

Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announces

BenzingaNov 7, 2023 08:33 ET

12 Health Care Stocks Moving In Monday's Pre-Market Session

GainersMiromatrix Medical (NASDAQ:MIRO) stock rose 223.1% to $3.36 during Monday's pre-market session. The company's market cap stands at $91.7 million. Eargo (NASDAQ:EAR) stock rose 54.16% to $2.59.

BenzingaOct 30, 2023 09:05 ET

Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer

Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announces a poster presentation on the Company's Pan-RAS platform at the American Association for Cancer Research (AACR) Special Conference in Breast Cancer Research, held October 19th to 22nd at the Westin San Diego Bayview.

GlobeNewswireOct 23, 2023 08:30 ET

Qualigen Therapeutics Partners With TD2 For Phase 1 Clinical Development Of QN-302 For The Treatment Of Advanced Or Metastatic Solid Tumors

Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, announced

BenzingaAug 17, 2023 08:33 ET

Qualigen Therapeutics Q2 EPS $(0.69) Up From $(1.10) YoY, Sales $1.63M Up From $1.43M YoY

Qualigen Therapeutics (NASDAQ:QLGN) reported quarterly losses of $(0.69) per share. This is a 37.27 percent increase over losses of $(1.10) per share from the same period last year. The company report

BenzingaAug 15, 2023 08:52 ET

Earnings Flash (QLGN) QUALIGEN THERAPEUTICS Reports Q2 Revenue $1.6M

08:31 AM EDT, 08/15/2023 (MT Newswires) -- Earnings Flash (QLGN) QUALIGEN THERAPEUTICS Reports Q2 Revenue $1.6M

MT NewswiresAug 15, 2023 08:31 ET

Qualigen Therapeutics 2Q Loss/Shr 69c >QLGN

Qualigen Therapeutics 2Q Loss/Shr 69c >QLGN

Dow JonesAug 15, 2023 08:30 ET

Qualigen Gains IND Clearance for Solid Tumors Candidate

Seeking AlphaAug 1, 2023 10:24 ET